Literature DB >> 33570213

YAP-TEAD up-regulates IRS2 expression to induce and deteriorate oesophageal cancer.

Xiangming Xu1, Jiao Nie1, Lin Lu1, Chao Du1, Fansheng Meng1, Duannuo Song1.   

Abstract

Oesophageal cancer (EC) represents a significant cause of cancer worldwide. Yes-associated protein (YAP) is reported to correlate with the initiation of multiple cancers including EC, but the underlying mechanism remains elusive. The current study aimed to investigate the molecular mechanism of YAP-TEAD in the occurrence and progression of EC. EC tissues and cells were obtained, followed by determination of the expression of YAP, c-Jun, pc-Jun and IRS2. The effect of YAP-TEAD on the biological EC cell processes was explored through gain- and loss-of-function approaches. The interaction between YAP and TEAD was detected by co-immunoprecipitation. The binding of TEAD to the c-Jun promoter was determined using chromatin immunoprecipitation. Tumour formation in the nude mice was detected in order to ascertain the effect of YAP and IRS2 in vivo. We found elevated YAP in the EC tissues and cells. YAP silencing led to a decrease in EC cell proliferation, invasion and sphere formation. YAP-TEAD complex bound to the promotor of c-Jun, and c-Jun led to an increase in the expression of IRS2 through the JNK/c-Jun pathway. Additionally, pc-Jun and phosphorylated JNK were localized in the nuclear in addition to displaying enhanced expression in the EC tissues. IRS2 overexpression negated the inhibition of cell proliferation, invasion and sphere formation triggering YAP silencing. YAP up-regulated IRS2 and aggravated EC in vivo. Taken together, YAP-TEAD activates the JNK/c-Jun pathway to up-regulate IRS2, ultimately promoting EC progression. Therefore, YAP-TEAD inhibition could be a promising therapeutic approach for EC treatment.
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Entities:  

Keywords:  IRS2; JNK/c-Jun pathway; TEAD; YAP; oesophageal cancer

Year:  2021        PMID: 33570213      PMCID: PMC7933937          DOI: 10.1111/jcmm.16266

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  43 in total

1.  Daucosterol induces autophagic-dependent apoptosis in prostate cancer via JNK activation.

Authors:  Ping Gao; Xiaopeng Huang; Tingting Liao; Guangsen Li; Xujun Yu; Yaodong You; Yuxing Huang
Journal:  Biosci Trends       Date:  2019-04-02       Impact factor: 2.400

2.  Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.

Authors:  Xiaojiang Cui; Hyun-Jung Kim; Isere Kuiatse; Heetae Kim; Powel H Brown; Adrian V Lee
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

3.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.

Authors:  Yi Liu-Chittenden; Bo Huang; Joong Sup Shim; Qian Chen; Se-Jin Lee; Robert A Anders; Jun O Liu; Duojia Pan
Journal:  Genes Dev       Date:  2012-06-07       Impact factor: 11.361

4.  Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.

Authors:  Kristina B Emdal; Anna-Kathrine Pedersen; Dorte B Bekker-Jensen; Alicia Lundby; Shana Claeys; Katleen De Preter; Frank Speleman; Chiara Francavilla; Jesper V Olsen
Journal:  Sci Signal       Date:  2018-11-20       Impact factor: 8.192

5.  Elevated STC‑1 augments the invasiveness of triple‑negative breast cancer cells through activation of the JNK/c‑Jun signaling pathway.

Authors:  Jeonghun Han; Myeongjin Jeon; Incheol Shin; Sangmin Kim
Journal:  Oncol Rep       Date:  2016-07-26       Impact factor: 3.906

6.  Insulin receptor substrate-1 and Golgi phosphoprotein 3 are downstream targets of miR‑126 in esophageal squamous cell carcinoma.

Authors:  Haomiao Li; Fanyu Meng; Jun Ma; Yongkui Yu; Xionghuai Hua; Jianjun Qin; Yin Li
Journal:  Oncol Rep       Date:  2014-07-11       Impact factor: 3.906

7.  JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells.

Authors:  Marisa Granato; Roberta Santarelli; Lavinia V Lotti; Livia Di Renzo; Roberta Gonnella; Alessia Garufi; Pankaj Trivedi; Luigi Frati; Gabriella D'Orazi; Alberto Faggioni; Mara Cirone
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

8.  TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells.

Authors:  Dana Elster; Marie Tollot; Karin Schlegelmilch; Alessandro Ori; Andreas Rosenwald; Erik Sahai; Björn von Eyss
Journal:  Nat Commun       Date:  2018-08-06       Impact factor: 14.919

9.  ESCC ATLAS: A population wide compendium of biomarkers for Esophageal Squamous Cell Carcinoma.

Authors:  Asna Tungekar; Sumana Mandarthi; Pooja Rajendra Mandaviya; Veerendra P Gadekar; Ananthajith Tantry; Sowmya Kotian; Jyotshna Reddy; Divya Prabha; Sushma Bhat; Sweta Sahay; Roshan Mascarenhas; Raghavendra Rao Badkillaya; Manoj Kumar Nagasampige; Mohan Yelnadu; Harsh Pawar; Prashantha Hebbar; Manoj Kumar Kashyap
Journal:  Sci Rep       Date:  2018-08-24       Impact factor: 4.379

10.  IRS2 depletion inhibits cell proliferation and decreases hormone secretion in mouse granulosa cells.

Authors:  Lanjie Lei; Feng Han; Qiuyan Cui; Weifang Liao; Hui Liu; Gaopeng Guan; Lei Yang
Journal:  J Reprod Dev       Date:  2018-07-12       Impact factor: 2.214

View more
  4 in total

1.  C12orf59 Promotes Esophageal Squamous Cell Carcinoma Progression via YAP-Mediated Epithelial-Mesenchymal Transition.

Authors:  Chunhua Xu; Shan Lin; Yanxin Lu; Longyi Mao; Shi Li; Zesong Li
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers.

Authors:  Chungen Lan; Bo Ni; Tiansuo Zhao; Zekun Li; Junjin Wang; Ying Ma; Weidong Li; Xiuchao Wang
Journal:  Front Genet       Date:  2022-05-24       Impact factor: 4.772

Review 3.  TEAD4 as an Oncogene and a Mitochondrial Modulator.

Authors:  Sheng-Chieh Hsu; Ching-Yu Lin; Yen-Yi Lin; Colin C Collins; Chia-Lin Chen; Hsing-Jien Kung
Journal:  Front Cell Dev Biol       Date:  2022-05-05

4.  YAP-TEAD up-regulates IRS2 expression to induce and deteriorate oesophageal cancer.

Authors:  Xiangming Xu; Jiao Nie; Lin Lu; Chao Du; Fansheng Meng; Duannuo Song
Journal:  J Cell Mol Med       Date:  2021-02-11       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.